Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells
Open Access
- 28 March 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (19) , 27379-27393
Abstract
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cellsKeywords
This publication has 57 references indexed in Scilit:
- The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoEuropean Journal of Cancer, 2013
- Molecular features in arsenic-induced lung tumorsMolecular Cancer, 2013
- An overview of the c-MET signaling pathwayTherapeutic Advances in Medical Oncology, 2011
- Arsenic trioxide — An old drug rediscoveredBlood Reviews, 2010
- Arsenic Activates EGFR Pathway Signaling in the LungToxicological Sciences, 2009
- Arsenicosis: Diagnosis and treatmentIndian Journal of Dermatology, Venereology and Leprology, 2008
- Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trialInvestigational New Drugs, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- AP-1 in cell proliferation and survivalOncogene, 2001
- Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1Oncogene, 2000